France
· Delayed Price · Currency is EUR Ipsen Company Description
Ipsen S.A. operates as a biopharmaceutical company worldwide.
The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases.
The company was founded in 1929 and is based in Boulogne-Billancourt, France.
| Country | France |
| Founded | 1929 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5,358 |
| CEO | David Loew |
Contact Details
Address: 65, quai Georges Gorse Boulogne-Billancourt, 92100 France | |
| Phone | 33 1 58 33 50 00 |
| Website | ipsen.com |
Stock Details
| Ticker Symbol | IPN |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0010259150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Loew | MD, Chief Executive Officer and Director |
| Aymeric Le Chatelier | Executive Vice President and Chief Financial Officer |
| Dr. Aidan Murphy Ph.D. | Executive Vice President and Head of Technical Operations |
| Khalid Deojee | Senior Manager of Investor Relations |
| Francois Garnier | Executive Vice President of Legal Affairs, General Counsel and Chief Business Ethics Officer |
| Regis Mulot | Executive Vice President and Chief Human Resources Officer |
| Dominique Bery | Head of Nordics and Baltics |
| Bartosz Bednarz D.D.S. | Executive Vice President and Head of Global Product and Portfolio Strategy |
| Philippe Lopes-Fernandes CBO | Executive Vice President and Chief Business Officer |
| Dr. James Levine M.D., Ph.D. | President of Fondation Ipsen |